|
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Consistent with published functional data showing that tapasin promotes antigen presentation, as well as tumor immune recognition and destruction by CD8(+) CTLs, a reduction in tapasin expression is associated with tumor progression in CRC.
|
26310568 |
2015 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
A reduction of tapasin expression strongly correlated with venous invasion (AUC 0.682, OR 2.7, p = 0.002; 95% CI 1.7-5.0), lymphatic invasion (AUC 0.620, OR 2.0, p = 0.005; 95 % CI 1.3-3.3), distant metastasis (AUC 0.727, OR 2.9, p = 0.004; 95% CI 1.4-5.9) and an infiltrative tumor border configuration (AUC 0.621, OR 2.2, p = 0.017; 95% CI 1.2-4.4).
|
26310568 |
2015 |
|
Tumor Cell Invasion
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
TAP1, CNX, LMP7, Erp57 and Tapasin loss were significantly associated with tumor grading, lymph node metastasis and depth of invasion (P < 0.05).
|
21362330 |
2011 |
|
Systemic onset juvenile chronic arthritis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Tapasin gene polymorphism in systemic onset juvenile rheumatoid arthritis: a family-based case-control study.
|
15743475 |
2005 |
|
Small cell carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Thus, for immunotherapeutic approaches to target SCLC and other tumours with defects in the MHC class I antigen processing pathway it will be important to consider strategies that address tapasin-defects.
|
17143611 |
2007 |
|
Small cell carcinoma of lung
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The present study examines the expression of HLA, tapasin, transporter associated with antigen processing 1 (TAP1), and beta2 microglobulin in human small cell lung carcinoma and non-small cell lung carcinoma.
|
16140964 |
2005 |
|
Skin Ulcer
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Severe hypoglycaemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The rate of capillary glucose ≤70 mg/dL, the number of hypoglycemic episodes per 100 days of TPN, and the percentage of patients with non-severe hypoglycemia were significantly higher on GI group.No severe hypoglycemia was detected.
|
30930133 |
2020 |
|
Severe Combined Immunodeficiency
|
0.010 |
Biomarker
|
disease |
LHGDN |
A subject with a novel type I bare lymphocyte syndrome has tapasin deficiency due to deletion of 4 exons by Alu-mediated recombination.
|
12149238 |
2002 |
|
Septicemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The following characteristics were significantly associated with severe CKD: female gender (HR 1.34), older age (HR 1.38/10 year increment), catheter-related sepsis (HR 1.58), steroid maintenance immunosuppression (HR 1.50), graft failure (HR 1.76), ACR (HR 1.64), prolonged requirement for IV fluids (HR 2.12) or TPN (HR 1.94), and diabetes (HR 1.54).
|
28241392 |
2017 |
|
Sepsis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The following characteristics were significantly associated with severe CKD: female gender (HR 1.34), older age (HR 1.38/10 year increment), catheter-related sepsis (HR 1.58), steroid maintenance immunosuppression (HR 1.50), graft failure (HR 1.76), ACR (HR 1.64), prolonged requirement for IV fluids (HR 2.12) or TPN (HR 1.94), and diabetes (HR 1.54).
|
28241392 |
2017 |
|
Secretory diarrhea
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results suggest an anti-diarrheal activity of α-TPN due to its anticholinergic action, ability to block PGE<sub>2</sub> and GM1 receptors and interaction with cholera toxin in secretory diarrhea, making it a promising candidate drug for the treatment of diarrheal diseases.
|
30540974 |
2019 |
|
Secondary Neoplasm
|
0.010 |
GeneticVariation
|
group |
BEFREE |
The frequency of TAP1, LMP2 and tapasin loss varied between 33% of primary adenocarcinomas, 40% of HIN to approximately 67% of metastases.
|
14750179 |
2004 |
|
SEBASTIAN SYNDROME
|
0.010 |
Biomarker
|
disease |
BEFREE |
The villus height and crypt depth of the ileum in the SBS/TPN/ghrelin group were significantly higher than in the SBS/TPN group.
|
29966680 |
2018 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
We found significant associations between schizophrenia and TAP1 allele frequencies (P=9.95x10(-3), chi(2)=12.36) as well as TAPASIN allele frequencies (P=2.8x10(-2), chi(2)=5.3).
|
19217216 |
2009 |
|
Schizophrenia
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
We found significant associations between schizophrenia and TAP1 allele frequencies (P=9.95x10(-3), chi(2)=12.36) as well as TAPASIN allele frequencies (P=2.8x10(-2), chi(2)=5.3).
|
19217216 |
2009 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis.
|
21156761 |
2011 |
|
Respiratory Distress Syndrome, Newborn
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Controlling for patient characteristics and complexity of disease (comorbid intestinal atresia/perforation, necrotizing enterocolitis, and respiratory distress syndrome), we compared surgical outcomes (mortality, length of stay, and incidence of TPN cholestasis) by hospital volume based on quartile for gastroschisis cases treated per year.
|
28947327 |
2017 |
|
Respiratory Distress Syndrome, Adult
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Controlling for patient characteristics and complexity of disease (comorbid intestinal atresia/perforation, necrotizing enterocolitis, and respiratory distress syndrome), we compared surgical outcomes (mortality, length of stay, and incidence of TPN cholestasis) by hospital volume based on quartile for gastroschisis cases treated per year.
|
28947327 |
2017 |
|
Respiratory Distress Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Controlling for patient characteristics and complexity of disease (comorbid intestinal atresia/perforation, necrotizing enterocolitis, and respiratory distress syndrome), we compared surgical outcomes (mortality, length of stay, and incidence of TPN cholestasis) by hospital volume based on quartile for gastroschisis cases treated per year.
|
28947327 |
2017 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical staining of 51 formalin-fixed RCC lesions and autologous normal renal epithelium detected transporter associated with antigen processing (TAP)1 and tapasin deficiencies in 63 and 80% of the tumor lesions.
|
12738726 |
2003 |
|
Recurrent bronchitis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Pseudohyperkalemia Cardiff
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The present study aimed to explore the association between TAP, LMP and tapasin gene polymorphism and treatment response in chronic hepatitis C virus (CHC) patients.
|
29039469 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Notably, migration of cancer cell was significantly inhibited when treated with FIS-TPN formulations.
|
28004315 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
To deliver personalized RNA-based-therapy targeting oncogenic miRNAs that form part of this common PDAC miRNA over-expression signature, we packaged antimiR oligonucleotides against one of these miRNAs in tumor-penetrating nanocomplexes (TPN) targeting cell surface proteins on PDAC tumors.<b>Results:</b> As a validation for our pre-clinical strategy, the therapeutic potential of one of our nano-drugs, TPN-21, was first shown to decrease tumor cell growth and survival in PDO avatars for individual patients, then in their PDX avatars.<b>Conclusions:</b> This general approach appears suitable for co-clinical validation of personalized RNA medicine and paves the way to prospectively identify patients with eligible miRNA profiles for personalized RNA-based therapy.<i>Clin Cancer Res; 24(7); 1734-47.©2018 AACR</i>.
|
29330203 |
2018 |